• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Evaluation of cisplatin plasma levels in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

作者信息

Fleres Francesco, Saladino Edoardo, Catanoso Rosaria, Arcoraci Vincenzo, Mandolfino Tommaso, Cucinotta Eugenio, Macrì Antonio

机构信息

a Department of Human Pathology , University of Messina , Messina , Italy ;

b Department of S.A.S.T.A.S. , University of Messina , Messina , Italy ;

出版信息

Acta Chir Belg. 2016 Feb;116(1):19-22. doi: 10.1080/00015458.2015.1128204.

DOI:10.1080/00015458.2015.1128204
PMID:27385136
Abstract

Introduction Peritoneal surface malignancies have long been regarded as incurable, however, they can be treated with cytoreductive surgery in addition to hyperthermic intraperitoneal chemotherapy. This approach is associated with an increase in morbidity and mortality, unless hyperhydration is provided in a timely manner. Methods Cisplatin (CDDP) is the most widely used chemotherapeutic agent. Plasma levels of cisplatin (CDDP), a widely used chemotherapeutic agent, were measured before, during, and after the procedure. This was done in order to identify the window of highest risk as a function of drug concentrations, assuming a dose-dependent effect. Results Plasma levels of CDDP peak during perfusion. The concentration remains high until the 4th post-operative day and returns to pre-operative levels by the 7th post-operative day. Conclusions Our findings suggest that ensuring hyperhydration as well as infusing albumin and fresh frozen plasma may be of particular value for at least the first 4 days after the procedure.

摘要

相似文献

1
Evaluation of cisplatin plasma levels in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Acta Chir Belg. 2016 Feb;116(1):19-22. doi: 10.1080/00015458.2015.1128204.
2
Peritoneal metastases from small bowel cancer: Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in The Netherlands.小肠癌的腹膜转移:荷兰细胞减灭术和腹腔内热化疗的结果
Surgery. 2015 Jun;157(6):1023-7. doi: 10.1016/j.surg.2015.01.021. Epub 2015 Mar 25.
3
Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.复发性腹膜癌患者的重复细胞减灭术(CRS)联合腹腔热灌注化疗(HIPEC)
World J Surg Oncol. 2016 Feb 24;14(1):42. doi: 10.1186/s12957-016-0804-x.
4
Survival prognostic factors in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy treatment: analysis from a single oncological center.接受细胞减灭术和热腹腔内化疗的患者的生存预后因素:来自单一肿瘤中心的分析。
World J Surg Oncol. 2016 Mar 31;14:97. doi: 10.1186/s12957-016-0856-y.
5
Quality of life in peritoneal carcinomatosis: a prospective study in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).腹膜癌病患者的生活质量:一项针对接受细胞减灭术和腹腔内热灌注化疗(HIPEC)患者的前瞻性研究。
Dig Surg. 2014;31(4-5):334-40. doi: 10.1159/000369259. Epub 2014 Dec 3.
6
Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan.在日本一家专业中心,采用术前双向化疗联合细胞减灭术及术中腹腔热灌注化疗策略治疗胃源性腹膜癌患者的结局数据。
Ann Surg Oncol. 2014 Apr;21(4):1147-52. doi: 10.1245/s10434-013-3443-2. Epub 2013 Dec 20.
7
Outcome of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on patients with diaphragmatic involvement.细胞减灭术及腹腔内热灌注化疗对伴有膈肌受累患者的疗效
Ann Surg Oncol. 2015 May;22(5):1639-44. doi: 10.1245/s10434-014-4083-x. Epub 2014 Sep 13.
8
Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.阑尾癌腹膜转移行细胞减灭术联合热灌注化疗后的生存预测及预后因素
Ann Surg Oncol. 2014 Dec;21(13):4218-25. doi: 10.1245/s10434-014-3869-1. Epub 2014 Jul 2.
9
Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence.用于孤立性腹膜复发的减瘤手术与腹腔热灌注化疗相结合的迭代程序。
Int J Hyperthermia. 2014 Dec;30(8):565-9. doi: 10.3109/02656736.2014.974693.
10
Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.在探索性手术中不适合进行细胞减灭术和腹腔热灌注化疗的腹膜癌患者:危险因素、治疗选择及预后
Ann Surg Oncol. 2015 Apr;22(4):1236-42. doi: 10.1245/s10434-014-4148-x. Epub 2014 Oct 16.

引用本文的文献

1
Enhanced Recovery After Surgery for Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: A Systematic Review and Meta-Analysis.接受细胞减灭术和腹腔热灌注化疗患者的术后加速康复:一项系统评价和荟萃分析
Front Surg. 2021 Jul 21;8:713171. doi: 10.3389/fsurg.2021.713171. eCollection 2021.
2
Predictors of morbidity and mortality in patients submitted to cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for ovarian carcinomatosis: a multicenter study.接受减瘤手术联合腹腔热灌注化疗治疗卵巢癌转移患者的发病和死亡预测因素:一项多中心研究
Pleura Peritoneum. 2020 Dec 4;6(1):21-30. doi: 10.1515/pp-2020-0139. eCollection 2021 Mar.